Overview
QGEN market data
Price History
QGEN price chart
Valuation & Profitability
- P/E (TTM)
- 21.41 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.94 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.62 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 62.2% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $32.53 – $57.82 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $8.6K · P/B 2.58 · P/S 4.10.
Company News
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption AccelerateGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak; Says Qiagen’s FDA-Cleared QIAstat-Dx Gastrointestinal Panel 2 Can Detect Cyclospora Infections In About An Hour As Part Of A 16-Target Gastrointestinal Pathogens MenuBenzinga · Jul 15, 2026, 8:09 PM
QIAGEN Launches CE-IVDR-Certified QIAstat-Dx BCID GN Plus AMR Panel In EuropeBenzinga · Jul 14, 2026, 8:09 PM
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible TakeoverBenzinga · Jul 10, 2026, 1:30 PM
'Qiagen Draws Early Takeover Interest From EQT, Advent' - BloombergBenzinga · Jul 9, 2026, 2:25 PM
Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGRGlobenewswire Inc · Jul 6, 2026, 11:00 AM
Molecular Biology Enzymes, Reagents and Kits Market Size Worth USD 70.85 Billion by 2035 | SNS InsiderGlobenewswire Inc · Jul 3, 2026, 11:15 AM
Bloodstream Infection Testing Market Size to Reach USD 1,404.68 Million by 2035 | SNS InsiderGlobenewswire Inc · Jun 26, 2026, 11:00 AM
Morgan Stanley Upgrades Qiagen to Overweight, Raises Price Target to $42Benzinga · Jun 23, 2026, 5:45 PM
Qiagen Announces Global Launch Of QIA Agent AI Digital Assistant For ResearchersBenzinga · May 20, 2026, 8:20 PM